预约演示

Scancell enjoys stock bounce on back of phase 2 snapshot for DNA cancer vaccine

2023-09-19

临床2期疫苗临床结果免疫疗法

Patients received the cancer vaccine, dubbed SCIB1, via a needle-free device.

It’s been a good week cancerancell’s shareholders, as investors seized on early data from the biotech's phase 2 cancer vaccine trial to send its stock up 20%.

Preliminary data from the Scancellage of the study showed that the DNA vaccine, dubbed SCIB1, produced an 82% recancer rate across 11 patients with advanced melanoma when given in combination with checkpoint inhibitors. This exceeded the 70% milestone for objective response rate (ORR) set by the Oxford, U.K.-based company for the trial, according to a release (PDF).

The aim of the study was to see whether the vaccine could either induce new, or boost eSCIB1ng, immune responses. These responses could then be protadvanced melanomar environment by checkpoint inhibitors—in this case Bristol Myers Squibb’s Opdivo and Yervoy.

Patients received SCIB1 via a needle-free device. Of the nine patients who have shown a response with radiological imaging at a 13-week evaluation, the reductiontumorumor volume ranged from 31%-94%, the biotech said. Bristol Myers Squibbg tOpdivo the YervoyR of the Opdivo-Yervoy combo alone.

“Previous studies SCIB1ated that a response rate of 50% was the best that could be achieved in the real world setting for patients with unresectable metastatic melantumoras no other combination had improved on the response rates for doublet CPI alone,” Scancell CEO Opdivo-Yervoy said in the release. “Confirmation of this data in a larger cohort could make a significant impact on melanoma patient survival, especially as melanoma is now one of the most common cancers in young women.”

While it’s still early days for the study, the results appeared to be enough to get investors excited, sending the biotech’s stock up 20unresectable metastatic melanomaar stock bump on Monday, the company’s share price is still only sitting at 15 pence Scancell15 p.m. U.K. time on the London Stock Exchange’s AIM submarket.melanoma melanoma cancers

In total, the SCOPE trial is expected to recruit 87 participants. Around three-quarters of participants had been recruited as of July, with Scancell suggesting at the time that initial top-line data are likely to read out in the final quarter (PDF) of the year.

The company has another cancer vaccine, dubbed Modi-1, in a phase 2 dose-expansion trial as a monotherapy and in combination with checkpoint inhibitors. The study in ovarian, triple negative breast, renal, and head and neck cancers is due to read out next year.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构